COUGH is the #6 most commonly reported adverse reaction for SACUBITRIL AND VALSARTAN, manufactured by Novartis Pharmaceuticals Corporation. There are 7,820 FDA adverse event reports linking SACUBITRIL AND VALSARTAN to COUGH. This represents approximately 3.7% of all 209,561 adverse event reports for this drug.
SACUBITRIL AND VALSARTAN has an overall safety score of 85 out of 100. Patients taking SACUBITRIL AND VALSARTAN who experience cough should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
Reporting Frequency
COUGH7,820 of 209,561 reports
COUGH is moderately reported among SACUBITRIL AND VALSARTAN users, representing a notable but not dominant share of adverse events.
Other Side Effects of SACUBITRIL AND VALSARTAN
In addition to cough, the following adverse reactions have been reported for SACUBITRIL AND VALSARTAN:
COUGH has been reported as an adverse event in 7,820 FDA reports for SACUBITRIL AND VALSARTAN. This does not prove causation, but indicates an association observed in post-market surveillance data.
How common is COUGH with SACUBITRIL AND VALSARTAN?
COUGH accounts for approximately 3.7% of all adverse event reports for SACUBITRIL AND VALSARTAN, making it a notable side effect.
What should I do if I experience COUGH while taking SACUBITRIL AND VALSARTAN?
If you experience cough while taking SACUBITRIL AND VALSARTAN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.
Disclaimer: This analysis is based on FDA adverse event reports and is for informational purposes only. Reports do not prove causation. Always consult your healthcare provider.